1Ostroff RB, Nelson JC, Risperidone augmentation of selectiveserotonin reuptake inhibitors in major depression [J]. J Clin Psychiatry, 1999,60:256-259,
2Barbee JG, Conrad NJ. The effectiveness of olanzapine,risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder [ J ]. J Clin Psychiatry,2004,5 : 975-981.
3Papakostas GI, Peters TJ. Aripiprazole augmentation of selective serotonin reuptake inhlbitors for treatment-risistant major depressive disorder [ J ]. J Clin Psychiatry,2005,66 : 132.
4Lambert G. Johansson M, Agem H, et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catechoiamine hypothesis of mood disorders [J]. J Arch Gen Psychiatry,2005,57:787-793.
5Kapur S, Zipurski RB, Remington G. Clinical and theoretical implication of 5-HT2 and DA2 receptors occupancy of clozapine, risperidone,and olanzapine in schizophrenia [ J]. Am J Psychiatric Practice, 2003,9 : 376-384.
4Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry, 1999, 156 (12) :2017.
5Amsterdam JD, Homing-rohan M. Treatment algorithms in treatment resistant depression. Psychiatr Clin North Am, 1996,19:371-386.
6Lambert G, Johansson M, Agem H, et al . Reduced brain norepinephrine and dopanine release in treatment-refractory depressive illness evidence in support of the catechoiamine hypothesis of mood disor. J Arch Gen Psychiatry, 2005,57:787-793.
